Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H1 2020, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.
Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 16 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H1 2020, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.
Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 16 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Vancomycin-Resistant Enterococcus faecium Infections - Overview
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
Acurx Pharmaceuticals LLC
AimMax Therapeutics Inc
AnyGen Co Ltd
Aphios Corp
Arietis Corp
Armata Pharmaceuticals Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Helix BioMedix Inc
Hsiri Therapeutics LLC
Karveel Pharmaceuticals
MGB Biopharma Ltd
MicuRx Pharmaceuticals Inc
Naicons Srl
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Oragenics Inc
Ovensa Inc
QureTech Bio AB
Rebiotix Inc
Sealife PHARMA GMBH
Sentinella Pharmaceuticals Inc
Wockhardt Ltd
Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles
ACX-375C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGM-290 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APY-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDM-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
contezolid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GmPcide-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HT-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marinus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGBBP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Novo-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OG-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CLPP for Vancomycin Resistant Enterococci Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ftsz for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNP-021062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vancomycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WCK-4086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
Featured News & Press Releases
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Vancomycin-Resistant Enterococcus faecium Infections - Overview
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
Acurx Pharmaceuticals LLC
AimMax Therapeutics Inc
AnyGen Co Ltd
Aphios Corp
Arietis Corp
Armata Pharmaceuticals Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Helix BioMedix Inc
Hsiri Therapeutics LLC
Karveel Pharmaceuticals
MGB Biopharma Ltd
MicuRx Pharmaceuticals Inc
Naicons Srl
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Oragenics Inc
Ovensa Inc
QureTech Bio AB
Rebiotix Inc
Sealife PHARMA GMBH
Sentinella Pharmaceuticals Inc
Wockhardt Ltd
Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles
ACX-375C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGM-290 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APY-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDM-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
contezolid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GmPcide-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HT-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marinus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGBBP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Novo-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OG-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CLPP for Vancomycin Resistant Enterococci Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ftsz for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNP-021062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vancomycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WCK-4086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
Featured News & Press Releases
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Acurx Pharmaceuticals LLC, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AimMax Therapeutics Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AnyGen Co Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Arietis Corp, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Curza Global LLC, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Karveel Pharmaceuticals, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Naicons Srl, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Opal Biosciences Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Ovensa Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by QureTech Bio AB, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H1 2020
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Acurx Pharmaceuticals LLC, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AimMax Therapeutics Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AnyGen Co Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Arietis Corp, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Curza Global LLC, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Karveel Pharmaceuticals, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Naicons Srl, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Opal Biosciences Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Ovensa Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by QureTech Bio AB, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals Inc, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Acurx Pharmaceuticals LLC
AimMax Therapeutics Inc
AnyGen Co Ltd
Aphios Corp
Arietis Corp
Armata Pharmaceuticals Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Helix BioMedix Inc
Hsiri Therapeutics LLC
Karveel Pharmaceuticals
MGB Biopharma Ltd
MicuRx Pharmaceuticals Inc
Naicons Srl
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Oragenics Inc
Ovensa Inc
QureTech Bio AB
Rebiotix Inc
Sealife PHARMA GMBH
Sentinella Pharmaceuticals Inc
Wockhardt Ltd
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Acurx Pharmaceuticals LLC
AimMax Therapeutics Inc
AnyGen Co Ltd
Aphios Corp
Arietis Corp
Armata Pharmaceuticals Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Helix BioMedix Inc
Hsiri Therapeutics LLC
Karveel Pharmaceuticals
MGB Biopharma Ltd
MicuRx Pharmaceuticals Inc
Naicons Srl
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Oragenics Inc
Ovensa Inc
QureTech Bio AB
Rebiotix Inc
Sealife PHARMA GMBH
Sentinella Pharmaceuticals Inc
Wockhardt Ltd
